Developer docs
API playgroundTry for free, no card

Search company profiles

Drug Policy

Full company profile

uuid000hg2h

Namestring
Drug Policy
Legal namestring
Drug Policy Alliance
Websiteurl
drugpolicy.org
Company typeenum
Private
Founded yearint
2000
Descriptiontext

Drug Policy Alliance (DPA) is a U.S. 501(c)(3) nonprofit organization founded in 2000 and headquartered at 131 West 33rd Street, New York. The organization addresses the harms of drug use and drug criminalization through policy advocacy, organizing, and public education. Its operational footprint spans 51-100 employees and is led by Executive Director Kassandra Frederique, with founder Ethan Nadelmann credited as the organization's founder.

DPA's core offerings are not commercial products but a portfolio of advocacy and educational resources: comprehensive Drug Facts sheets covering substances including fentanyl, xylazine, nitazenes, cocaine, heroin, and marijuana; organized Issue Areas and Campaigns addressing overdose prevention, addiction treatment access, marijuana legalization, criminal justice reform, and removal of barriers to work, housing, and benefits; a Resource Library with drug war statistics and history; an interactive Drug Policy Impacts Map tracking decriminalization legislation across U.S. jurisdictions; a Take Action advocacy platform with petitions and legislator-contact tools; and a Membership Program. The underlying "technology" is an evidence-based harm reduction education and public health advocacy platform, supplemented by a digital supporter engagement stack spanning website, email newsletters, and major social platforms (Facebook, Twitter/X, Instagram, YouTube, TikTok, Bluesky), plus the annual Reform Conference.

DPA generates no product or service revenue. Its business model is donations and charitable contributions, including one-time donations, monthly recurring giving via the "Reformers Club," membership, Donor Advised Funds (DAFs), and grants from aligned foundations. The organization serves people directly impacted by drug criminalization, harm reduction service providers, and policymakers/elected officials, pursuing a horizontal segmentation approach grounded in evidence, health, equity, and human rights.

Short descriptiontext

Drug Policy Alliance is a 501(c)(3) nonprofit founded in 2000 that advocates for drug policy reform through evidence-based research, harm reduction education, and public health campaigns, serving communities affected by drug criminalization, harm reduction providers, and policymakers.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersNew York, United States
HQ citystring
New York
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
drug policy reform, harm reduction advocacy, overdose prevention, nonprofit health advocacy, marijuana legalization
Industry4 codes
1Substance Use Disorder Prevention & Recovery Services
CodeBPAGACAEPrimaryYes
2Substance Use Recovery & Harm Reduction Support Services
CodeBPAGAEAOPrimaryNo
3Behavioral Health & Substance Use Public Health Programs
CodeBPAIAJAKPrimaryNo
4Substance Use, Addiction & Harm Reduction Health Departments
CodeHLAJAAAMPrimaryNo
NAICS code2 codes
  • Social Advocacy Organizations8133
  • Human Rights Organizations813311
SIC code3 codes
  • Services-Social Services8300
  • Services-Health Services8000
  • Services-Membership Organizations8600
Product category
Drug Policy Advocacy
Revenue model1 record
1Donations and Charitable Contributions
TypeOthers
Description

Drug Policy Alliance operates as a 501(c)(3) nonprofit organization funded primarily through individual donations, charitable contributions, and grants from foundations aligned with their mission.

drugpolicy.org
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Personnel, Operations, Marketing or Sales, Technology or R&D
GTM typeB2C
B2C
Offering typeServices
Services
Core offering1 text field

Drug Policy Alliance is a 501(c)(3) nonprofit advocacy organization that promotes drug policies grounded in science, compassion, health, equity, and human rights. It delivers evidence-based educational resources, policy analysis, harm reduction information, and grassroots advocacy campaigns addressing overdose prevention, addiction treatment access, marijuana legalization, decriminalization, and removal of barriers to employment, housing, and benefits for people with drug convictions.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 2 values shown
  • Overdose deaths declined 27% in 2024 due in part to health interventions DPA advocates for
+1 more record
Product overview1 text field

Drug Policy Alliance (DPA) operates a nonprofit advocacy platform focused on drug policy reform, harm reduction, and overdose prevention. The organization functions as an educational and advocacy organization rather than a traditional technology company. Its primary offerings include comprehensive drug facts resources (factsheets on cocaine, fentanyl, xylazine, nitazenes, and other substances), organized issue areas and campaigns addressing key policy areas, a resource library with drug war statistics and history, an interactive drug policy impacts map, online take action campaigns for advocacy, and a membership program. The platform does not operate as a unified software product but rather as a collection of educational resources, advocacy tools, and community engagement features centered on advancing health-based drug policy.

Product and service6 records
1Drug Facts Resources
CategoryEducational Resource
Description

Comprehensive educational factsheets providing evidence-based information on drug effects, health impacts, treatment options, harm reduction strategies, and policy recommendations for various substances. Targeted at the public, affected communities, policymakers, and service providers.

2Issue Areas and Campaigns
CategoryAdvocacy Platform
Description

Organized advocacy campaigns addressing key drug policy issues including reducing fentanyl harms, preventing overdose deaths, increasing access to addiction services, ending criminal penalties, removing barriers to work and housing, regulating drugs for health and safety, legalizing marijuana, and centering health in foreign drug policy.

3Resource Library
CategoryKnowledge Resource
Description

Online library containing drug facts, drug war statistics, drug war history, and drug policy impact resources that document the effects of drug criminalization and inform advocacy efforts.

4Drug Policy Impacts Map
CategoryData Visualization Tool
Description

Interactive map tracking decriminalization legislation and drug policy impacts across jurisdictions in the United States.

5Take Action Campaigns
CategoryAdvocacy Action Platform
Description

Online petition and advocacy action platform enabling supporters to contact legislators about protecting funding for treatment and overdose prevention, ending marijuana criminalization, and supporting health-based drug policy approaches.

6Membership Program
CategorySubscription Service
Description

Organizational membership program enabling individuals to support the Drug Policy Alliance's mission through donations, recurring giving, and engagement with advocacy campaigns.

Scale indicator2 records

Each record includes

Type, Value, Description, Source

Partnership4 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-06-19
Description

Coalition partner in Virginia marijuana legalization advocacy efforts. The coalition is urging Virginia Governor Abigail Spanberger and state lawmakers to remove provisions that would increase fines for public cannabis consumption as part of compromise legislation.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-06-19
Description

Coalition partner advocating for marijuana policy reform in Virginia, working together with DPA and other organizations to promote equitable cannabis legalization.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-06-19
Description

Coalition partner in Virginia marijuana legalization advocacy, working collaboratively on policy reform efforts.

Strategic tierMinorTypeOthers
Description

DPA advocates for maintaining and protecting funding from SAMHSA for overdose prevention, addiction treatment, and harm reduction services. The administration has been cutting SAMHSA funding, which DPA is working to prevent.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Long-standing national nonprofit addressing substance use and addiction through family support, education, and policy advocacy. Comparable in scale, audience (families affected by addiction), and policy orientation.

TypeDirect peer
Description

National nonprofit focused on ending the addiction crisis through evidence-based treatment access and stigma reduction. Comparable as a national drug policy and treatment access advocacy organization.

TypeDirect peer
Description

National nonprofit advancing harm-reduction interventions including naloxone distribution, syringe access, and drug user health. Overlaps closely with DPA on harm reduction advocacy and overdose prevention.

TypeBroad incumbent
Description

Larger civil liberties organization with criminal-justice and drug-decriminalization portfolios. Comparable as a coalition partner and broader advocacy incumbent that DPA plugs into for state-level work (e.g., ACLU of Virginia partnership).

TypeDirect peer
Description

The leading US marijuana legalization advocacy organization and an active DPA coalition partner. Highly comparable as a single-issue drug policy reform nonprofit that drives state-level legislative campaigns and grassroots mobilization.

TypeDirect peer
Description

Major US marijuana policy reform organization and DPA coalition partner. Directly comparable in mission, federal-state advocacy model, donor base, and target legislator audience.

TypeEmerging player
Description

US nonprofit advocating from a prevention/abstinence-oriented stance on drug policy. Comparable as a peer advocacy organization operating in the same policy arena but on the opposing side of the reform debate.

TypeBroad incumbent
Description

Large national coalition representing community drug-prevention efforts with significant federal funding. Comparable as a peer advocacy organization with strong federal relationships but oriented to prevention rather than harm reduction.

TypeRegional player
Description

Global network of NGOs focused on drug policy reform at the UN and international level. Comparable in mission but operates internationally, complementing DPA's US-only footprint on foreign drug policy issues.

TypeOthers
Description

Major philanthropic funder of drug policy reform globally and a likely donor to organizations like DPA. Comparable as a drug policy ecosystem participant rather than a direct operational peer.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Drug Policy

Drug Policy Advocacydrugpolicy.org

Drug Policy Alliance is a 501(c)(3) nonprofit founded in 2000 that advocates for drug policy reform through evidence-based research, harm reduction education, and public health campaigns, serving communities affected by drug criminalization, harm reduction providers, and policymakers.

What Drug Policy does

Drug Policy Alliance (DPA) is a U.S. 501(c)(3) nonprofit organization founded in 2000 and headquartered at 131 West 33rd Street, New York. The organization addresses the harms of drug use and drug criminalization through policy advocacy, organizing, and public education. Its operational footprint spans 51-100 employees and is led by Executive Director Kassandra Frederique, with founder Ethan Nadelmann credited as the organization's founder.

DPA's core offerings are not commercial products but a portfolio of advocacy and educational resources: comprehensive Drug Facts sheets covering substances including fentanyl, xylazine, nitazenes, cocaine, heroin, and marijuana; organized Issue Areas and Campaigns addressing overdose prevention, addiction treatment access, marijuana legalization, criminal justice reform, and removal of barriers to work, housing, and benefits; a Resource Library with drug war statistics and history; an interactive Drug Policy Impacts Map tracking decriminalization legislation across U.S. jurisdictions; a Take Action advocacy platform with petitions and legislator-contact tools; and a Membership Program. The underlying "technology" is an evidence-based harm reduction education and public health advocacy platform, supplemented by a digital supporter engagement stack spanning website, email newsletters, and major social platforms (Facebook, Twitter/X, Instagram, YouTube, TikTok, Bluesky), plus the annual Reform Conference.

DPA generates no product or service revenue. Its business model is donations and charitable contributions, including one-time donations, monthly recurring giving via the "Reformers Club," membership, Donor Advised Funds (DAFs), and grants from aligned foundations. The organization serves people directly impacted by drug criminalization, harm reduction service providers, and policymakers/elected officials, pursuing a horizontal segmentation approach grounded in evidence, health, equity, and human rights.

Drug Policy firmographics

Firmographics
Name
Drug Policy
Legal name
Drug Policy Alliance
Website
https://drugpolicy.org
Company type
Private
Founded year
2000
Operating status
Operating
Headcount range
51–100 employees
Short description
Drug Policy Alliance is a 501(c)(3) nonprofit founded in 2000 that advocates for drug policy reform through evidence-based research, harm reduction education, and public health campaigns, serving communities affected by drug criminalization, harm reduction providers, and policymakers.
Ownership category
akta.pro rank

Drug Policy industry classification

Industry
Product category
Drug Policy Advocacy
NAICS
Social Advocacy Organizations (8133), Human Rights Organizations (813311)
SIC
Services-Social Services (8300), Services-Health Services (8000), Services-Membership Organizations (8600)
akta.pro primary industry
Substance Use Disorder Prevention & Recovery Services (BPAGACAE)
akta.pro secondary industries
Substance Use Recovery & Harm Reduction Support Services (BPAGAEAO), Behavioral Health & Substance Use Public Health Programs (BPAIAJAK), Substance Use, Addiction & Harm Reduction Health Departments (HLAJAAAM)

Keywords

  • Drug policy reform
  • Harm reduction advocacy
  • Overdose prevention
  • Nonprofit health advocacy
  • Marijuana legalization

Where Drug Policy is headquartered

Location

Headquarters

HQ city
New York
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Drug Policy business model

Business model
GTM type
B2C
Offering type
Services
Cost components
Personnel, Operations, Marketing or Sales, Technology or R&D

Revenue model

  1. Donations and Charitable Contributions: Drug Policy Alliance operates as a 501(c)(3) nonprofit organization funded primarily through individual donations, charitable contributions, and grants from foundations aligned with their mission.

Distribution channels2 records

Marketing channels5 records

Drug Policy product offering

Product offering

Core offering

Drug Policy Alliance is a 501(c)(3) nonprofit advocacy organization that promotes drug policies grounded in science, compassion, health, equity, and human rights. It delivers evidence-based educational resources, policy analysis, harm reduction information, and grassroots advocacy campaigns addressing overdose prevention, addiction treatment access, marijuana legalization, decriminalization, and removal of barriers to employment, housing, and benefits for people with drug convictions.

Product overview

Drug Policy Alliance (DPA) operates a nonprofit advocacy platform focused on drug policy reform, harm reduction, and overdose prevention. The organization functions as an educational and advocacy organization rather than a traditional technology company. Its primary offerings include comprehensive drug facts resources (factsheets on cocaine, fentanyl, xylazine, nitazenes, and other substances), organized issue areas and campaigns addressing key policy areas, a resource library with drug war statistics and history, an interactive drug policy impacts map, online take action campaigns for advocacy, and a membership program. The platform does not operate as a unified software product but rather as a collection of educational resources, advocacy tools, and community engagement features centered on advancing health-based drug policy.

Differentiator

Problem solved

Functional benefit

Products and services

  • Drug Facts Resources Comprehensive educational factsheets providing evidence-based information on drug effects, health impacts, treatment options, harm reduction strategies, and policy recommendations for various substances. Targeted at the public, affected communities, policymakers, and service providers.
  • Issue Areas and Campaigns Organized advocacy campaigns addressing key drug policy issues including reducing fentanyl harms, preventing overdose deaths, increasing access to addiction services, ending criminal penalties, removing barriers to work and housing, regulating drugs for health and safety, legalizing marijuana, and centering health in foreign drug policy.
  • Resource Library Online library containing drug facts, drug war statistics, drug war history, and drug policy impact resources that document the effects of drug criminalization and inform advocacy efforts.
  • Drug Policy Impacts Map Interactive map tracking decriminalization legislation and drug policy impacts across jurisdictions in the United States.
  • Take Action Campaigns Online petition and advocacy action platform enabling supporters to contact legislators about protecting funding for treatment and overdose prevention, ending marijuana criminalization, and supporting health-based drug policy approaches.
  • Membership Program Organizational membership program enabling individuals to support the Drug Policy Alliance's mission through donations, recurring giving, and engagement with advocacy campaigns.

Quantifiable outcome

  • Overdose deaths declined 27% in 2024 due in part to health interventions DPA advocates for
  • +1 more outcomes

Companies that use Drug Policy

Customer profile

Segments3 records

Ideal customer profiles1 record

Drug Policy technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Drug Policy partnerships and signals

Strategic signal

Partnerships

Four partnerships are on record, tiered core and minor.

  • ACLU of VirginiacoreStrategic or Co-development Partner · 19 June 2026Coalition partner in Virginia marijuana legalization advocacy efforts. The coalition is urging Virginia Governor Abigail Spanberger and state lawmakers to remove provisions that would increase fines for public cannabis consumption as part of compromise legislation.
  • NORMLcoreStrategic or Co-development Partner · 19 June 2026Coalition partner advocating for marijuana policy reform in Virginia, working together with DPA and other organizations to promote equitable cannabis legalization.
  • Marijuana Policy ProjectcoreStrategic or Co-development Partner · 19 June 2026Coalition partner in Virginia marijuana legalization advocacy, working collaboratively on policy reform efforts.
  • SAMHSA (Substance Abuse and Mental Health Services Administration)minorOthersDPA advocates for maintaining and protecting funding from SAMHSA for overdose prevention, addiction treatment, and harm reduction services. The administration has been cutting SAMHSA funding, which DPA is working to prevent.

Scale indicators2 records

Recent moves6 records

Expansion highlights5 records

Drug Policy competitors and assessment

Company assessment

Direct peers

  • Partnership to End Addiction: Long-standing national nonprofit addressing substance use and addiction through family support, education, and policy advocacy. Comparable in scale, audience (families affected by addiction), and policy orientation.
  • Shatterproof: National nonprofit focused on ending the addiction crisis through evidence-based treatment access and stigma reduction. Comparable as a national drug policy and treatment access advocacy organization.
  • National Harm Reduction Coalition: National nonprofit advancing harm-reduction interventions including naloxone distribution, syringe access, and drug user health. Overlaps closely with DPA on harm reduction advocacy and overdose prevention.
  • NORML (National Organization for the Reform of Marijuana Laws): The leading US marijuana legalization advocacy organization and an active DPA coalition partner. Highly comparable as a single-issue drug policy reform nonprofit that drives state-level legislative campaigns and grassroots mobilization.
  • Marijuana Policy Project: Major US marijuana policy reform organization and DPA coalition partner. Directly comparable in mission, federal-state advocacy model, donor base, and target legislator audience.

Broad incumbents

  • ACLU (American Civil Liberties Union): Larger civil liberties organization with criminal-justice and drug-decriminalization portfolios. Comparable as a coalition partner and broader advocacy incumbent that DPA plugs into for state-level work (e.g., ACLU of Virginia partnership).
  • CADCA (Community Anti-Drug Coalitions of America): Large national coalition representing community drug-prevention efforts with significant federal funding. Comparable as a peer advocacy organization with strong federal relationships but oriented to prevention rather than harm reduction.

Emerging players

  • Drug Free America Foundation: US nonprofit advocating from a prevention/abstinence-oriented stance on drug policy. Comparable as a peer advocacy organization operating in the same policy arena but on the opposing side of the reform debate.

Regional players

  • International Drug Policy Consortium (IDPC): Global network of NGOs focused on drug policy reform at the UN and international level. Comparable in mission but operates internationally, complementing DPA's US-only footprint on foreign drug policy issues.

Others

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

Drug Policy social profiles

Digital presence

Drug Policy financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Drug Policy leadership team

Management profile

Number of profiles

Drug Policy funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Drug Policy M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Drug Policy

What does Drug Policy do?

Drug Policy Alliance is a 501(c)(3) nonprofit advocacy organization that promotes drug policies grounded in science, compassion, health, equity, and human rights. It delivers evidence-based educational resources, policy analysis, harm reduction information, and grassroots advocacy campaigns addressing overdose prevention, addiction treatment access, marijuana legalization, decriminalization, and removal of barriers to employment, housing, and benefits for people with drug convictions.

Is Drug Policy a public or private company?

Drug Policy is a private company. It is classified as nonprofit foundation owned and is currently operating.

When was Drug Policy founded?

Drug Policy was founded in 2000. It employs 51 to 100 people.

Where is Drug Policy based?

Drug Policy is headquartered in New York, United States, in the North America region.

How does Drug Policy make money?

One revenue line is on record: donations and Charitable Contributions.

Who are Drug Policy's main competitors?

Direct peers on record are Partnership to End Addiction, Shatterproof, National Harm Reduction Coalition, NORML (National Organization for the Reform of Marijuana Laws) and Marijuana Policy Project. Broad incumbents are ACLU (American Civil Liberties Union) and CADCA (Community Anti-Drug Coalitions of America). Drug Free America Foundation is listed as an emerging player. International Drug Policy Consortium (IDPC) is listed as a regional player. Open Society Foundations – Drug Policy Program is listed as an others.

Does Drug Policy have an API?

No public API is recorded for Drug Policy.

What industry is Drug Policy in?

Drug Policy's product category is Drug Policy Advocacy. Its primary akta.pro industry code is BPAGACAE, Substance Use Disorder Prevention & Recovery Services, with a secondary code of BPAGAEAO, Substance Use Recovery & Harm Reduction Support Services. Its NAICS code is 8133 and its SIC code is 8300.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Marijuana MomentAdvocacy Groups Push Back Against Virginia Proposal To Increase Public Marijuana Use Fines In Sales Legalization MeasureA coalition of marijuana reform and social justice organizations, including the ACLU of Virginia, NORML, Drug Policy Alliance, and Marijuana Policy Project, are urging Virginia Governor Abigail Spanberger and state lawmakers to remove a provision that would increase fines for public cannabis consumption from $25 to $250 as part of a compromise deal to legalize adult-use marijuana sales. The groups argue the 900 percent penalty increase would disproportionately harm Black and brown communities, create debt for low-income individuals, and potentially trigger cascading consequences in housing, employment, and immigration. The Virginia Senate is set to vote on the budget legislation containing the cannabis provisions on Monday, with the new plan also setting a launch date of July 1, 2027 for recreational sales and increasing the marijuana excise tax.CBS NewsTrump administration ends funding for fentanyl test strips, baffling public health groups: "It doesn't make sense"The Trump administration, through the Substance Abuse and Mental Health Services Administration (SAMHSA), has ended federal funding for fentanyl test strips, reversing a policy position it held as recently as July 2025; the change stems from an executive order declaring SAMHSA funding cannot be used for programs that "only facilitate illegal drug use." The policy change has already resulted in direct budget cuts to harm reduction organizations, including the Kentucky Harm Reduction Coalition losing a $400,000 grant and Fyrebird Recovery losing a $4,000 grant, leaving organizations with dwindling supplies of test strips. Public health advocates warn the funding cuts could reverse the sharp decline in overdose deaths, which fell from 111,000 in 2023 to about 68,000 for the 12-month period ending November 2025, and strip away tools that have been proven to save lives.Drug Policy AllianceLegalize Marijuana RightThe Drug Policy Alliance advocates for marijuana legalization reforms that prioritize public health, consumer safety, and justice over corporate profits. The organization urges the federal government to deschedule marijuana from the Controlled Substances Act to end criminalization and support communities harmed by prohibition.Time Out WorldwideA first look inside the House of Cannabis, NYC’s new weed museumThe House of Cannabis (THC NYC), a new four-story museum dedicated to cannabis culture and science, is set to open in Soho on April 7. Co-founded by Marcelle and Robert Frey, the 25,000-square-foot venue features immersive exhibits addressing social justice issues, art, and cultivation, partnering with the Drug Policy Alliance for educational content.PR NewswireN.M. Legalized Cannabis, A Half Billion Dollar IndustryA commissioned report by Ultra Health®, supported by the Drug Policy Alliance and Rio Grande Foundation, estimates that legalizing cannabis in New Mexico could generate a half-billion dollar industry and create over 11,400 jobs. The report projects the legalized cannabis market would produce three times the annual revenue of New Mexico's pecan crop while removing hundreds of millions from the criminal market. Comparing to established markets, Washington and Colorado are expected to reach $1.4 billion and $833 million respectively in 2016.Business InsiderThese stock photos are trying to change the way people view pot smokersThe Drug Policy Alliance released a stock photo collection of legal cannabis users to counter media stereotypes. The photos, free for editorial use, aim to improve the industry's image, as 2.5 million US users no longer match the typical stoner portrayal. Activists hope the gallery helps shift perceptions as public opinion changes.Business InsiderThe Real Story About Marijuana Legalization According To A Top Insider In The MovementEthan Nadelmann, founder of the Drug Policy Alliance, said marijuana legalization activists must avoid overconfidence and use ballot initiatives as the primary strategy. He noted California and Oregon are likely next, and emphasized combining legalization advocacy with youth safety measures.Business InsiderFive People Who Are Leading The Fight To Legalize MarijuanaFive individuals leading the U.S. marijuana legalization movement are profiled, including Allen St. Pierre of NORML, Ethan Nadelmann of the Drug Policy Alliance, Peter B. Lewis, Justin Ross Hartfield, and Alison Holcomb. Their roles span advocacy, philanthropy, and political campaigns, with Lewis having donated roughly $40 million since 1996.